Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Phase of product development
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Product description

Phase of product development

4 evidence topics · 4 sources

Investigational status

“Zanzalintinib is an investigational agent that is not approved for any use” (opens the source at this quote in a new tab)

Investigational-use disclaimer

“The safety and efficacy of these investigational compounds and/or investigational uses have not been established.” (opens the source at this quote in a new tab)

Regulatory submission: NDA submitted December 2025

“In December 2025, we submitted a New Drug Application (NDA) to the FDA for zanzalintinib in combination with atezolizumab” (opens the source at this quote in a new tab)

Updated FDA target action date

“The updated Prescription Drug User Fee Act action date is March 3, 2027.” (opens the source at this quote in a new tab)

Launch

No evidence found.